Nitric oxide synthase is expressed in experimental malignant glioma and influences tumour blood flow.
The distribution and function of nitric oxide synthase (NOS) was studied in the rodent C6 implantation glioma model. Using a histochemical stain for NADPH diaphorase, which colocalises with NOS, morphological studies revealed non homogenous staining of the constituent tumour cells and the neoplastic endothelium. Immunocytochemical staining for macrophages (ED1, ED2) showed dense positivity at the tumour brain interface with more patchy positivity within the tumour mass. This finding suggests that both macrophages, which are known to produce large amounts of NO, and the C6 cells contribute to the NADPH diaphorase positivity. Administration of the NOS inhibitor Ng-nitro-L-argine methyl ester (L-NAME) significantly reduced both tumour (40%) and contralateral local cerebral blood flow (20%) compared to control animals. These findings demonstrate that (i) NOS is present in experimental malignant glioma; (ii) NO mediated mechanisms contribute to tumour blood vessel dilatation and blood flow regulation; and (iii) using this model there is a significant differential sensitivity of the tumour and brain parenchymal vascular beds to a NOS inhibitor. Further investigations are required to determine the potential therapeutic and biological relevance of these findings and the relative contributions of tumour cells, neoplastic endothelium and reactive macrophages to NO mechanism in gliomas.
Whittle
I R
IR
Department of Clinical Neurosciences, Western General Hospital, Edinburgh, Scotland, U.K.
Collins
F
F
Kelly
P A
PA
Ritchie
I
I
Ironside
J W
JW
D000818:Animals; D001932:Brain Neoplasms / Q000201:enzymology*; D002560:Cerebrovascular Circulation / Q000502:physiology*; D004195:Disease Models, Animal; D005910:Glioma / Q000201:enzymology*; D007150:Immunohistochemistry; D009252:NADPH Dehydrogenase / Q000737:chemistry; D019001:Nitric Oxide Synthase / Q000378:metabolism*
D019001:Nitric Oxide Synthase; D009252:NADPH Dehydrogenase